Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Merry A. Danaceau is active.

Publication


Featured researches published by Merry A. Danaceau.


The New England Journal of Medicine | 1998

Differential Behavioral Effects of Gonadal Steroids in Women with and in Those without Premenstrual Syndrome

Peter J. Schmidt; Lynnette K. Nieman; Merry A. Danaceau; Linda F. Adams; David R. Rubinow

BACKGROUND The symptoms of women with premenstrual syndrome improve in response to suppression of ovarian function, although these women have no evidence of ovarian dysfunction. We undertook a study to determine the role of estrogen and progesterone in this syndrome. METHODS We first studied the effect of ovarian suppression with leuprolide, an agonist analogue of gonadotropin-releasing hormone, or placebo on symptoms in 20 women with the premenstrual syndrome. Ten women whose symptoms improved during leuprolide treatment were given estradiol and progesterone in a double-blind, crossover design, each for four weeks, during continued leuprolide administration. Women without premenstrual syndrome (normal women) participated in a similar protocol. Outcomes were assessed on the basis of daily self-reports by the patients and biweekly rater-administered symptom-rating scales. RESULTS The 10 women with premenstrual syndrome who were given leuprolide had a significant decrease in symptoms as compared with base-line values and with values for the 10 women who were given placebo. The 10 women with premenstrual syndrome who were given leuprolide plus estradiol or progesterone had a significant recurrence of symptoms, but no changes in mood occurred in 15 normal women who received the same regimen or in 5 women with premenstrual syndrome who were given placebo hormone during continued leuprolide administration. CONCLUSIONS In women with premenstrual syndrome, the occurrence of symptoms represents an abnormal response to normal hormonal changes.


Neuropsychopharmacology | 1997

Fluoxetine in the Treatment of Premenstrual Dysphoria

Tung Ping Su; Peter Schmidt; Merry A. Danaceau; Marie B. Tobin; Donald L. Rosenstein; Dennis L. Murphy; David R. Rubinow

We performed a double-blind, placebo-controlled, crossover trial of fluoxetine in 17 women with prospectively confirmed PMS who also met criteria for premenstrual dysphoric disorder (PMDD). A subset of 10 women with PMDD and an additional 10 controls participated in a single-dose m-chlorophenylpiperazine (m-CPP) challenge during the follicular and luteal phases of the menstrual cycle. We evaluated the ability of the acute behavioral response to luteal phase m-CPP administration to predict therapeutic response to fluoxetine. Compared with baseline, fluoxetine, but not placebo, treatment significantly improved both emotional and physical symptoms. We identified 11 (65%) fluoxetine responders who no longer met diagnostic criteria for PMDD during fluoxetine but remained symptomatic during placebo treatment. In addition, acute symptomatic improvement also occurred following m-CPP administration in 7 of 10 women with PMDD. The small number of m-CPP nonresponders did not respond to fluoxetine either. Our findings confirm that fluoxetine is an effective treatment of PMDD.


Neuropsychopharmacology | 2005

Testosterone Suppression of CRH-Stimulated Cortisol in Men

David R. Rubinow; Catherine A. Roca; Peter J. Schmidt; Merry A. Danaceau; Karen Putnam; Giovanni Cizza; George P. Chrousos; Lynnette K. Nieman

Despite observations of age-dependent sexual dimorphisms in hypothalamic–pituitary–adrenal (HPA) axis activity, the role of androgens in the regulation of HPA axis activity in men has not been examined. We assessed this role by performing CRH stimulation tests in 10 men (ages 18–45 years) during gonadal suppression with leuprolide acetate and during testosterone addition to leuprolide. CRH-stimulated cortisol levels as well as peak cortisol and greatest cortisol excursion were significantly lower (p<0.05, 0.005, and 0.01, respectively) during testosterone replacement compared with the induced hypogonadal condition (leuprolide plus placebo); cortisol area under the curve was lower at a trend level (p<0.1). Paradoxically, CRH-stimulated corticotropin (ACTH) was increased significantly during testosterone replacement (p<0.05). The cortisol : ACTH ratio, a measure of adrenal sensitivity, was lower during testosterone replacement (p<0.1). A mixed effects regression model showed that testosterone but not estradiol or CBG significantly contributed to the variance of cortisol. These data demonstrate that testosterone regulates CRH-stimulated HPA axis activity in men, with the divergent effects on ACTH and cortisol suggesting a peripheral (adrenal) locus for the suppressive effects on cortisol. Our results further demonstrate that the enhanced stimulated HPA axis activity previously described in young men compared with young women cannot be ascribed to an activational upregulation of the axis by testosterone.


Psychoneuroendocrinology | 2002

Basal plasma hormone levels in depressed perimenopausal women

Peter J. Schmidt; Jean H. Murphy; Nazli Haq; Merry A. Danaceau; L.Simpson St. Clair

BACKGROUND An association between abnormal changes in reproductive endocrine function during the perimenopause and the onset of depression in some women has been suggested but remains controversial. METHODS We examined basal plasma hormone levels in two samples of women with well characterized, first onset depression (major or minor) during the perimenopause and matched comparison groups of asymptomatic women. Results were compared by analysis of variance. RESULTS No significant diagnosis-related differences were observed in plasma hormone measures of the following: follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), estrone (E1), total (T) or free testosterone (FT), or the E2/LH ratio. We did identify significantly lower morning plasma dehydroepiandrosterone (DHEA) and its sulphated metabolite DHEA-S (but not cortisol) levels in the depressed women compared to the non-depressed comparison group. Women with hot flushes (regardless of the presence of depression) were significantly older than women without flushes, had significantly higher plasma levels of FT, LH and FSH, and had significantly lower E2/LH ratios. CONCLUSIONS Women with first onset depression during the perimenopause are not distinguished from controls on the basis of basal hormone measures of ovarian estrogens, testosterone, or gonadotropins. However, perimenopause-related changes in E2 may interact with low levels of DHEA in some women to increase their vulnerability to develop depression. In contrast to perimenopause-related vasomotor symptoms, depression during the perimenopause is not associated with a simple hormone deficiency state. The relatively low levels of E2 and E1 in the depressed women may have met statistical significance in a much larger and homogenous sample.


Archives of Womens Mental Health | 2004

Stressful life events, personal losses, and perimenopause-related depression

Peter J. Schmidt; Jean H. Murphy; Nazli Haq; David R. Rubinow; Merry A. Danaceau

SummaryWe compared the number and quality of life events reported by depressed perimenopausal women and a non-depressed comparison group. Additionally, we examined the effects of the presence of hot flushes on life event reports. All women were 44–55 years old, had irregular menses and elevated plasma gonadotropin levels. The Psychiatric Epidemiology Research Interview recorded both the frequency of occurrence and the desirability of life events experienced by the women during the six months prior to the interview. Depressed perimenopausal women (n=50) reported significantly more undesirable events [Student’s t-test (unpaired) with Bonferroni correction, t98=3.9, p=0.001] but not more exit events (e.g., divorce, last child leaving home or death in family) (t98=0.9, p=NS) compared to the non-depressed women (n=50). There were no effects of hot flushes on these diagnostic differences. The “empty nest” syndrome does not appear to be relevant in the development of perimenopausal depression. Nevertheless, independent of the presence of hot flushes, perimenopausal depressed women are more likely to report both negative life events and diminished self esteem.


Neuropsychopharmacology | 2002

The effects of gender and gonadal steroids on the neuroendocrine and temperature response to m-chlorophenylpiperazine in leuprolide-induced hypogonadism in women and men.

Peter Schmidt; Jamuna Raju; Merry A. Danaceau; Dennis L. Murphy; Robin E. Berlin

Studies of the effects of gender and gonadal steroids on serotonergic activity in humans are few in number and often contradictory. We examined the neuroendocrine and core temperature response to a serotonergic stimulus, m-chlorophenylpiperazine (m-CPP) (0.08 mg/kg body weight, IV), in asymptomatic female and male volunteers during induced hypogonadism (leuprolide acetate) and hormone replacement (estradiol (E2) or progesterone (P4) in women; testosterone (T) in men).Compared with the hypogonadal state, basal prolactin (PRL) secretion was significantly higher during both P4 and E2 replacement (p < .05) in women and during T replacement in men (p < .05). m-CPP stimulated PRL secretion was significantly greater only during P4 (p < .05) but not E2 (women) or T (men) replacement, compared with hypogonadism. Basal but not stimulated plasma growth hormone (GH) levels were significantly higher during P4 in women and T in men (p < .05), and no significant differences in basal or m-CPP stimulated plasma levels of ACTH or cortisol were observed. Finally, basal core temperatures were significantly higher during P4 replacement compared with either E2 replacement or the hypogonadal condition (p < .01) in women, with no differences observed in men. Comparisons of measures by gender (and matched for baseline plasma T levels) revealed that during the hypogonadal state m-CPP–stimulated GH secretion was significantly greater (p < .01) and m-CPP–stimulated ACTH (p < .05) and cortisol (p < .01) significantly less in women compared with men.Although our data are limited to those components of the central serotonergic system influenced by m-CPP administration, our findings suggest the following: the regulatory effects of gonadal steroids on serotonergic function are modest in humans during leuprolide-induced hypogonadism; menstrual cycle phase effects of serotonergic agents on PRL secretion may reflect both the effects of P4 and E2; the effects of P4 in humans may occur without E2 priming of the progesterone receptor; and gender differences in GH secretion occur independent of the presence of gonadal steroids.


Psychoneuroendocrinology | 2001

Effects of gonadal steroids on peripheral benzodiazepine receptor density in women with PMS and controls

Robert C. Daly; Peter Schmidt; Candace L. Davis; Merry A. Danaceau; David R. Rubinow

BACKGROUND GABA receptor-modifying neurosteroids may play a role in premenstrual syndrome (PMS). The peripheral benzodiazepine receptor (PBR) both regulates the formation of neurosteroids and is, in animals, regulated by ovarian steroids. Alterations in PBR density have been observed in association with several psychiatric disorders. METHODS We examined the effects of gonadal steroids on lymphocytic PBR density in nine women with prospectively confirmed PMS and nine controls. PBR densities were measured during three pharmacologically controlled conditions: gonadotropin releasing hormone agonist (Lupron)-induced hypogonadism, Lupron plus estradiol, and Lupron plus progesterone replacement. Blood samples were obtained after six weeks of Lupron alone and after 3-4 weeks of estradiol and progesterone replacement. RESULTS No significant hormone state-related changes in PBR density were observed (ANOVA-R: phase-F(2,32)=1.5, P=0.2). Despite mood symptom development in the subjects with PMS, PBR density did not differ in women with PMS compared to controls across hormonal states (ANOVA-R: F(1,16)=0.6, P=0.4). CONCLUSIONS PBR densities are not altered in women with PMS and are not changed significantly by selective gonadal steroid administration. Changes in PBR density would not appear to underlie the differential sensitivity to the mood destabilizing effects of ovarian steroids in PMS.


NeuroImage | 2001

The gonadal steroid hormones, estrogen and progesterone, affect functional connectivity and hippocampal function during working memory

Karen Faith Berman; Peter Schmidt; Andreas Meyer-Lindenberg; Neha Dixit; Philip Kohn; Merry A. Danaceau; Daniel R. Weinberger; David R. Rubinow

Introduction: There is considerable evidence from animal studies that gonadal steroid hormones modulate neuronal activity and influence behavior. In nonhuman primates estrogen affects frontal lobe function and working memory [l]; in hippocampi of rodents made hypogonadal by ovariectomy, estrogen treatment increases excitability, dendritic spine density, and synapse formation, while progesterone treatment decreases them [2]. However in humans, while behavioral and cognitive evidence has accrued, there is little direct neurobiological dam. To elucidate the neurophysiology of hormonally-related cognitive and behavioral effects in humans, we have carried out a series of studies analogous to those in animals, using functional nemoimaging in young women during three distinct, pharmacologically-induced hormonal states: 1) ovarian suppression (reversible menopause), 2) ovarian suppression plus estrogen replacement, and 3) ovarian suppression plus progesterone replacement. Ovarian suppression was induced with a gonadotopin-releasing hormone agonist, resulting in depletion of endogenous estrogen and progesterone. We previously reported [3] in young women that during ovarian suppression (i.e. in the absence of estrogen and progesterone) there was a marked attenuation of the activation pattern typically seen during the Wisconsin Card Sort, particularly in dorsolateral prefrontal cortex. When either progesterone or estrogen was replaced, the activation pattern normalized, with a return of the prefrontal activation. The present study used the same hormonal manipulation protocol and an N-back task to focus on functional connectivity and hippocampal function during working memory.


American Journal of Psychiatry | 2000

Effects of Gonadal Steroids in Women With a History of Postpartum Depression

Miki Bloch; Peter Schmidt; Merry A. Danaceau; Jean H. Murphy; Lynnette K. Nieman; David R. Rubinow


American Journal of Obstetrics and Gynecology | 2000

Estrogen replacement in perimenopause-related depression: A preliminary report ☆

Peter Schmidt; Lynnette K. Nieman; Merry A. Danaceau; Marie B. Tobin; Catherine A. Roca; Jean H. Murphy; David R. Rubinow

Collaboration


Dive into the Merry A. Danaceau's collaboration.

Top Co-Authors

Avatar

David R. Rubinow

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Peter J. Schmidt

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Peter Schmidt

Michigan State University

View shared research outputs
Top Co-Authors

Avatar

Catherine A. Roca

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Dennis L. Murphy

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Jean H. Murphy

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Lynnette K. Nieman

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Nazli Haq

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Karen Faith Berman

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Robert C. Daly

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge